Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Turn Therapeutics Inc. (TTRX)

Turn Therapeutics Q3 net loss widens to $6.2 million from $1.9 million

Negative Impact 3 of 5 earnings

Turn Therapeutics reported a third-quarter 2026 net loss of $6.2 million, or $(0.21) per share, up from $1.9 million, or $(0.07) per share, a year earlier. The company said its $10.4 million in cash as of September 30, 2026 is expected to fund operations into the third quarter of 2027, which matters to shareholders given the higher loss and the need for further capital.

Key points

  • Q3 2026 net loss was $6.2 million, or $(0.21) per basic and diluted share, versus $1.9 million, or $(0.07), in Q3 2025
  • Net loss from change in fair value of derivative liability instrument was $3.3 million in the quarter, compared with none in the prior-year period
  • Cash and cash equivalents were $10.4 million at September 30, 2026, with operations expected to be funded into the third quarter of 2027

The filing

CompanyTurn Therapeutics Inc. (TTRX)
Form8-K, current report
Filed with the SECNov 9, 2026, 7:00 AM ET
Accession number0001213900-26-117180

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:10 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.